| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Rafael Rosell | Q30003989 |
| P2093 | author name string | Santiago Viteri | |
| Daniela Morales-Espinosa | |||
| Niki Karachaliou | |||
| P2860 | cites work | The biology and treatment of EML4-ALK non-small cell lung cancer | Q24632625 |
| LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer | Q27026346 | ||
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. | Q27851702 | ||
| Optimal detection of ALK rearranged lung adenocarcinomas | Q44979559 | ||
| More on crizotinib. | Q53081043 | ||
| Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. | Q54620289 | ||
| Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers | Q27851710 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. | Q27852553 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Benchmarking of mutation diagnostics in clinical lung cancer specimens | Q28740430 | ||
| BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations | Q28756824 | ||
| Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 | ||
| Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer | Q33860904 | ||
| Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. | Q34116750 | ||
| Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis | Q34339890 | ||
| Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay | Q34762839 | ||
| Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. | Q36068326 | ||
| Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods | Q36635602 | ||
| TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma | Q37401151 | ||
| Tyrosine kinase gene rearrangements in epithelial malignancies | Q37515966 | ||
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | Q37606591 | ||
| Anaplastic lymphoma kinase in human cancer | Q37866541 | ||
| Irreversible protein kinase inhibitors | Q37886215 | ||
| Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence | Q37976901 | ||
| Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. | Q38110796 | ||
| Genetics and biomarkers in personalisation of lung cancer treatment | Q38131166 | ||
| Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model | Q39188098 | ||
| The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition | Q39254036 | ||
| HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors | Q39263953 | ||
| Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations | Q39263992 | ||
| Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation | Q39297840 | ||
| Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells | Q39413086 | ||
| FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. | Q39571776 | ||
| Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer | Q39574492 | ||
| Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor | Q39695840 | ||
| Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance | Q39850353 | ||
| Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer | Q41837868 | ||
| Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer | Q42716713 | ||
| P433 | issue | 7 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | 807-815 | |
| P577 | publication date | 2014-03-10 | |
| P1433 | published in | Expert Review of Anticancer Therapy | Q2999044 |
| P1476 | title | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond | |
| P478 | volume | 14 |
| Q39278116 | Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer |
| Q61455304 | Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age |
| Q58573308 | MicroRNA-133a downregulated EGFR expression in human non-small cell lung cancer cells via AKT/ERK signaling |
| Q39095285 | Pharmacological management of relapsed/refractory NSCLC with chemical drugs |
| Q92236871 | Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives |
| Q39139907 | Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics |
| Q37046602 | The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer |
Search more.